Replimune Group Stock Performance
| REPL Stock | USD 7.14 -0.44 -5.80% |
The company secures a Beta (Market Risk) of -0.16, which attests to relatively modest fluctuations relative to the market. As returns on the market increase, returns on Replimune tend to move in the opposite direction, though by a smaller magnitude. During a bear market, however, Replimune is likely to outperform the market. At this point, Replimune Group has a negative expected return of -0.4%. Please make sure to confirm Replimune's relationship between the Kurtosis and day typical price, to decide if Replimune Group's performance from the past will be repeated in the future.
Risk-Adjusted Performance
Weak
Weak | Strong |
Replimune Group has delivered negative risk-adjusted returns across the last 90 days, suggesting that volatility was not compensated by return. Used correctly, this score helps investors distinguish between raw price movement and actual return efficiency. Despite uncertain performance in the last few months, the stock's basic indicators remain quite persistent, which may send shares a bit higher in April 2026. The latest mess may also be a sign of long-standing up-swing for the company's institutional investors. Learn More
Actual Historical Performance (%)
One Day Return 3.08 | Five Day Return -10.02 | Year To Date Return -17.30 | Ten Year Return -51.45 | All Time Return -51.45 |
1 | Replimune to Present at the 44 th Annual J.P. Morgan Healthcare Conference | 12/18/2025 |
2 | Acquisition by Andrew Schwendenman of 10000 shares of Replimune subject to Rule 16 b-3 | 12/19/2025 |
3 | Acquisition by Emily Hill of 67500 shares of Replimune at 8.4 subject to Rule 16 b-3 | 12/26/2025 |
4 | Disposition of 9154 shares by Emily Hill of Replimune at 5.37 subject to Rule 16 b-3 | 12/30/2025 |
5 | Is Replimune Group A Risky Investment - | 01/05/2026 |
6 | Replimune Highlights RP 1, RP 2 Progress Ahead of JPM Conference - Tip Ranks | 01/12/2026 |
7 | Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update | 02/03/2026 |
8 | Wall Street Analysts Predict a 65.72 percent Upside in Replimune Group Heres What You Should Know | 02/12/2026 |
9 | Disposition of 25000 shares by Astley-sparke Philip of Replimune subject to Rule 16 b-3 | 02/18/2026 |
10 | Acquisition by Emily Hill of 60000 shares of Replimune subject to Rule 16 b-3 | 02/23/2026 |
11 | Replimune Group Trading 11.1 percent Higher Heres Why | 03/06/2026 |
12 | Acquisition by Dhingra Kapil of 3169 shares of Replimune at 1.75 subject to Rule 16 b-3 | 03/13/2026 |
| Begin Period Cash Flow | 76.2 M | |
| Total Cashflows From Investing Activities | -23.8 M |
Replimune | Build portfolio with Replimune Stock |
Relative Risk vs. Return Landscape
If you had invested $ 966.00 in Replimune Group on December 17, 2025 and sold it today you would have lost $ 252.00 from holding Replimune Group or given up 26.09% of portfolio value over 90 days. Replimune Group does not currently generate positive expected returns and carries 4.7012% risk (volatility on return distribution) over a 90-day horizon. In different words, 42% of stocks are less volatile than Replimune, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Target Price Odds to finish over Current Price
Historical analysis shows that Replimune Stock price tends to gravitate toward a long-run average, consistent with the well-known mean reversion effect. While this is useful for forecasting, some stocks are persistently mispriced, often reflecting additional risk factors that justify the observed spread.
| Current Price | Horizon | Target Price | Odds moving above the current price in 90 days |
| 7.14 | 90 days | 7.14 | about 86.49 |
Based on our quantitative model, the chance of Replimune moving above the current price in 90 days from now is about 86.49 (This distribution for Replimune Group illustrates how likely Replimune Stock is to reach various price levels over 90 days).
Replimune Price Density |
| Price |
Predictive Modules for Replimune
Investors analyzing Replimune Group can draw on many different stock market forecasting techniques. While no approach eliminates uncertainty, comparing the outputs of diverse models helps investors calibrate expectations and make more informed decisions in the face of market unpredictability.The mean reversion framework for Replimune is built on the premise that markets are not perfectly efficient and that prices periodically overshoot their intrinsic value in both directions.
Primary Risk Indicators
Investors in the stock market have faced considerable volatility over the past two decades. Replimune has reflected this environment with periods of sharp price declines and strong recoveries. Tracking Replimune's fundamental risk indicators and adjusting hedges accordingly can help protect portfolios that include Replimune Group.α | Alpha over Dow Jones | -0.5286 | |
β | Beta against Dow Jones | -0.16 | |
σ | Overall volatility | 1.07 | |
Ir | Information ratio | -0.1088 |
Investor Alerts and Insights
Alerts for Replimune are designed to surface the most relevant stock developments for investors. Replimune Group notifications flag significant changes in market conditions, fundamentals, and technical signals that may require action.| Replimune Group generated a negative expected return over the last 90 days | |
| Replimune Group has high historical volatility and very poor performance | |
| Replimune Group has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was -247.3 M with profit before overhead, payroll, taxes, and interest of 0. | |
| Replimune Group currently holds about 395.08 M in cash with -192.25 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Replimune Group Trading 11.1 percent Higher Heres Why |
Price Density Drivers
Price movements in Replimune are influenced by the tension between bullish and bearish market participants. When short-sellers increase pressure, long holders often reassess their positions, driving volatility higher. Key market indicators are shown below.
| Common Stock Shares Outstanding | 80.6 M | |
| Cash And Short Term Investments | 483.8 M |
Replimune Fundamentals Growth
The financial health of Replimune is the primary driver of Replimune Stock market performance. Investors evaluate revenue trends, earnings growth, profit margins, and debt levels to form their outlook on Replimune Stock.
| Return On Equity | -0.91 | |||
| Return On Asset | -0.43 | |||
| Current Valuation | 397.6 M | |||
| Shares Outstanding | 82.57 M | |||
| Price To Book | 2.80 X | |||
| EBITDA | -253.92 M | |||
| Net Income | -247.3 M | |||
| Cash And Equivalents | 395.08 M | |||
| Cash Per Share | 8.01 X | |||
| Total Debt | 76.17 M | |||
| Debt To Equity | 0.08 % | |||
| Current Ratio | 19.79 X | |||
| Book Value Per Share | 2.64 X | |||
| Cash Flow From Operations | -192.25 M | |||
| Earnings Per Share | -3.44 X | |||
| Market Capitalization | 589.57 M | |||
| Total Asset | 551.33 M | |||
| Retained Earnings | -948.58 M | |||
| Working Capital | 433.52 M | |||
Performance Metrics & Calculation Methodology
Replimune performance is measured on a risk-adjusted basis against benchmarks. Consistency across periods improves confidence in structural behavior. Replimune shows ROE of -90.88%, ROA of -43.24%.
Reported values for Replimune Group are derived from periodic company reporting and market reference feeds and then standardized by Macroaxis analytics. Professional analyst research is incorporated when coverage is available. Refresh times depend on source availability. Return and risk statistics are calculated from historical price series.